Ozempic is the brand name for semaglutide injection, a GLP-1 receptor agonist manufactured by Novo Nordisk. As of 2026, the FDA has approved Ozempic for three indications: improving blood sugar control in adults with type 2 diabetes, reducing major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established cardiovascular disease, and reducing the risk of kidney disease progression in adults with type 2 diabetes and chronic kidney disease. The January 2025 kidney disease approval makes Ozempic the most broadly indicated GLP-1 receptor agonist currently on the US market.
Wegovy is the same semaglutide molecule at a higher 2.4 mg weekly dose, but it carries a separate FDA label for chronic weight management in adults with obesity or overweight plus a weight-related condition. Because Medicare Part D is prohibited by the Medicare Modernization Act of 2003 from covering drugs used for weight loss, Ozempic and Wegovy face completely different Medicare coverage rules in 2026. Patients who see Ozempic denied by Medicare should confirm whether their prescription cites a diabetes or cardiovascular ICD-10 code, not a weight-loss code. Rybelsus is the oral tablet form of semaglutide approved for type 2 diabetes and is also covered by Medicare Part D under diabetes formularies.
The Inflation Reduction Act of 2022 selected semaglutide (Ozempic, Rybelsus, and Wegovy) for the second round of Medicare drug price negotiation, with negotiated prices scheduled to take effect on January 1, 2027. No Maximum Fair Price has been set for Ozempic in 2026 under the IRA. For 2026, the main financial levers are the $2,100 annual Part D out-of-pocket cap, the NovoCare savings card for commercially insured patients, and the NovoCare patient assistance program for uninsured patients. Medicare beneficiaries with Part D coverage and diabetes should also ask their plan about the Medicare Prescription Payment Plan, which spreads Part D out-of-pocket spending evenly across the calendar year rather than concentrating it early in the benefit period.
What Medicare and Ozempic Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same medicare and ozempic can cost many times more at a hospital than at your local pharmacy:
2026 Medicare and Ozempic Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash, no insurance) | $950 - $1,100 per month (2026) | GoodRx and chain-level discounts apply; Costco typically lowest at ~$985; CVS highest at ~$1,089 |
| Medicare Part D (2026, diabetes indication only) | $0 - $250 per month, capped at $2,100 per year | After plan deductible (up to $615 in 2026), you pay 25% coinsurance until $2,100 annual OOP cap. Requires prior authorization and type 2 diabetes diagnosis or cardiovascular indication. |
| Commercial insurance (employer or marketplace plan) | $25 - $350 per month after prior authorization | Prior authorization required by most plans; step therapy (must try metformin first) is common. With the Ozempic savings card: as low as $25 per month. |
| Novo Nordisk savings card (commercially insured only) | $25 per month (max $100/month savings) | Commercial insurance required; Medicare, Medicaid, TRICARE, VA excluded by federal anti-kickback law. Subject to plan accumulator policies. |
| Medicaid | $1 - $4 per prescription (with prior authorization) | All state Medicaid programs cover Ozempic for type 2 diabetes; prior authorization and step therapy requirements vary by state. Medicaid copays are set by state income limits. |
Retail prices reflect 2026 pharmacy survey and GoodRx data. Part D costs depend on your plan's formulary tier, deductible, and where you are in your benefit year. All amounts are 2026 estimates.
Source: CMS Medicare Part D 2026 benefit parameters, Novo Nordisk NovoCare, GoodRx 2026
Why Hospitals Charge So Much
Ozempic is a self-administered, once-weekly subcutaneous injection that patients fill at an outpatient pharmacy and inject at home. Inpatient hospital billing for Ozempic is uncommon, but it does occur when a patient is admitted for a diabetes complication and the hospital's pharmacy dispenses an Ozempic pen from its formulary. When that happens, the facility charge frequently appears at $1,500 to $4,000 for a single pen, compared to a wholesale acquisition cost near $750 to $850 in 2026. The markup reflects facility overhead, pharmacy handling, nursing administration time, and the hospital's internal chargemaster rate, which is not the same as the retail pharmacy rate.
Patients who receive an inpatient bill showing Ozempic at several multiples of the retail price should request a fully itemized bill and identify the National Drug Code (NDC) listed. The 2026 retail acquisition cost for Ozempic can be verified against the manufacturer's published wholesale pricing and CMS drug pricing files. Charges significantly above the retail range are routinely challenged by hospital billing advocates and often reduced or waived, particularly if the patient's primary insurance has already paid the plan-approved rate and the remaining balance is a facility markup that the insurer did not authorize.
Patient Assistance Programs
Novo Nordisk runs two programs that lower the cost of Ozempic for patients who cannot afford it. The savings card targets commercially insured patients; the NovoCare patient assistance program targets uninsured patients with household income at or below 200 percent of the federal poverty level. Medicare and Medicaid beneficiaries have access only to the income-based patient assistance program, not the savings card, due to the federal anti-kickback statute (42 U.S.C. Section 1320a-7b). The retail cash price without insurance is approximately $998 per month in 2026. A qualifying patient with no insurance and income at 200 percent FPL could receive Ozempic free, saving roughly $11,976 per year.
Patient assistance programs for Medicare and Ozempic| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Ozempic Savings Card (NovoCare Diabetes Savings Card Program) | $25 per month (max $100/month savings) for commercially insured patients with type 2 diabetes | novocare.com/eligibility/diabetes-savings-card.html |
| Novo Nordisk Patient Assistance Program (NovoCare PAP): Ozempic for uninsured patients | Free Ozempic for uninsured patients with household income at or below 200% FPL. Medicare Part D enrollees are not eligible if their plan covers Ozempic. | diabetespap.novocare.com |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies; savings vary by pharmacy and pen strength | needymeds.org |
The Ozempic manufacturer coupon (savings card) is barred by federal law from being used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. This prohibition comes from the federal anti-kickback statute (42 U.S.C. Section 1320a-7b). Medicare and Medicaid beneficiaries must use the income-based Novo Nordisk Patient Assistance Program instead. Note: As of 2026, Novo Nordisk restricts Ozempic PAP eligibility for uninsured patients to 200 percent FPL (not 400 percent), and Medicare Part D enrollees are generally ineligible for the PAP once their plan covers Ozempic.
Source: Novo Nordisk NovoCare patient program pages, NeedyMeds.org, HHS 2026 Federal Poverty Guidelines
Medicare Part D
Medicare Part D covers Ozempic for type 2 diabetes and cardiovascular risk reduction as of 2026. Plans place Ozempic on a specialty or non-preferred brand tier in their formulary, which means you will pay a percentage of the drug's cost (coinsurance) rather than a flat copay. The 2026 annual Part D out-of-pocket cap is $2,100, established by the Inflation Reduction Act of 2022. Once your cumulative out-of-pocket spending on all covered Part D drugs reaches $2,100 in a calendar year, you pay $0 for covered drugs for the rest of that year. The maximum Part D deductible any plan may charge in 2026 is $615. Many plans have lower or no deductibles. Your actual coinsurance rate for Ozempic will depend on which Part D plan you are enrolled in and which formulary tier the plan assigns to semaglutide.
Medicare Part D does not cover Ozempic when the sole indication on the prescription is weight loss. Federal statute (42 U.S.C. Section 1395w-102(e)(2)(A)) expressly excludes drugs used for weight loss, appetite suppression, or obesity from Part D coverage. In March 2024, the Centers for Medicare and Medicaid Services clarified that Medicare may cover semaglutide (Wegovy, not Ozempic) when prescribed to reduce cardiovascular events in patients with established heart disease and a BMI over 27, but that exception does not apply to Ozempic's label. The Medicare GLP-1 Bridge program launching July 1, 2026 provides Wegovy and Zepbound at $50 per month for eligible Part D enrollees seeking weight-loss treatment, but Ozempic is specifically excluded because it does not carry an obesity indication.
Prior authorization is standard for Ozempic under Medicare Part D plans in 2026. Your prescriber must submit clinical documentation confirming a type 2 diabetes diagnosis, which typically includes recent HbA1c lab values and a history of antidiabetic treatment. Many plans also apply step therapy, requiring documentation that you tried a first-line agent such as metformin before advancing to a GLP-1 receptor agonist. If your plan denies Ozempic, you have the right to file a formulary exception request or a coverage determination appeal. Medicare requires standard appeals to be processed within 7 days and expedited appeals (for urgent cases) within 72 hours. If denied at the plan level, you can escalate to an Independent Review Entity (IRE) through the Medicare.gov appeals process.
Common Medicare and Ozempic Billing Errors
If you receive a bill for Ozempic higher than expected under Medicare Part D or commercial insurance, check for these issues before paying in 2026:
- Prior authorization not obtained or lapsed: if your prescriber's office did not submit a PA request or the PA expired, your plan may process the claim as a non-covered drug and bill you the full cash price.
- Ozempic billed under a weight-loss ICD-10 code (such as E66.9 for obesity) instead of a diabetes code (E11.x): Medicare Part D will deny the claim if the diagnosis code signals weight loss, even when the patient does have type 2 diabetes. Ask your prescriber to verify the ICD-10 code on the prescription.
- Charged the 25% coinsurance rate after reaching the $2,100 annual Part D out-of-pocket cap: once you cross $2,100 in 2026, you owe $0 for covered Part D drugs for the rest of the calendar year. If your pharmacy charges you after you hit the cap, contact your Part D plan immediately.
- Savings card not applied even though you are commercially insured and eligible: ask the pharmacist to re-run the claim using the Ozempic savings card BIN and PCN numbers, which are printed on the card from novocare.com.
- Multi-pen pack billed as multiple separate fills, resulting in multiple copay charges for what should be a single monthly prescription: one Ozempic pen contains four weekly doses; one pen equals one month's supply and should equal one copay.
Frequently Asked Questions
Does Medicare cover Ozempic for type 2 diabetes in 2026?
Yes. Medicare Part D covers Ozempic (semaglutide) when prescribed for type 2 diabetes or to reduce cardiovascular risk in adults with type 2 diabetes and established heart disease. Coverage requires prior authorization from most Part D plans, and many plans apply step therapy requiring documentation that you tried metformin first. Your out-of-pocket cost depends on your plan's formulary tier, but the 2026 annual Part D out-of-pocket cap is $2,100, after which you pay $0 for covered drugs the rest of the year.
Will Medicare cover Ozempic for weight loss in 2026?
No. Federal law (the Medicare Modernization Act of 2003) bars Medicare Part D from covering drugs used for weight loss, appetite suppression, or obesity. Because Ozempic's FDA label is for type 2 diabetes, not obesity, Medicare covers it only for the diabetes indication. The new Medicare GLP-1 Bridge program launching July 1, 2026 offers Wegovy and Zepbound for weight loss at $50 per month, but Ozempic is excluded because it does not have an obesity label.
What is the difference between Ozempic and Wegovy for Medicare coverage purposes?
Ozempic and Wegovy both contain semaglutide, but they carry different FDA labels, different doses, and different Medicare coverage rules. Ozempic (up to 2 mg weekly) is labeled for type 2 diabetes and cardiovascular risk reduction, so Medicare Part D covers it for diabetes patients. Wegovy (2.4 mg weekly) is labeled for chronic weight management, so Medicare historically excluded it under the anti-obesity drug exclusion. In 2024, CMS allowed Medicare to cover Wegovy for cardiovascular risk reduction in patients with established heart disease. For 2026, Wegovy is also covered under the new Medicare GLP-1 Bridge at $50 per month for weight loss. Ozempic is not in the GLP-1 Bridge because it lacks an obesity label.
How do I apply for the Novo Nordisk patient assistance program for Ozempic?
The Novo Nordisk NovoCare Patient Assistance Program provides free Ozempic for uninsured patients with household income at or below 200 percent of the 2026 federal poverty level. To apply: (1) Visit diabetespap.novocare.com or call 1-866-310-7549. (2) Complete the patient application online. (3) Gather proof of income (tax return or four consecutive pay stubs), proof of US residency, a valid Ozempic prescription, and a Medicaid denial letter if applicable. (4) Your prescriber completes the provider section via a secure link. Processing takes about 2 business days and, if approved, Ozempic ships to your home within 5 business days. Note: if your Medicare Part D plan already covers Ozempic, you are generally ineligible for the PAP.
Can I use the Ozempic savings card if I have Medicare?
No. The Ozempic savings card through Novo Nordisk is available only to patients with commercial (private) insurance. Medicare, Medicaid, TRICARE, and VA beneficiaries are barred by federal anti-kickback law (42 U.S.C. Section 1320a-7b) from using manufacturer copay savings cards. If you are on Medicare and cannot afford Ozempic, your options are: applying for the NovoCare Patient Assistance Program (if uninsured or if your Part D does not cover Ozempic and your income is at or below 200 percent FPL), applying for Medicare Extra Help (Low Income Subsidy), or asking your prescriber about a preferred formulary alternative.
Is there a generic or biosimilar for Ozempic in 2026?
No. No FDA-approved generic or biosimilar semaglutide exists in the United States as of 2026. Novo Nordisk's US patent on Ozempic extends to approximately 2031. Generic semaglutide is available in some countries (India, Canada) but cannot be legally imported for personal use. Compounded semaglutide from FDA-registered outsourcing facilities was widely available in 2024-2025 but the FDA declared the Ozempic shortage resolved in early 2025, and access to compounded semaglutide in 2026 is significantly restricted. Ask your prescriber about generic alternatives within the GLP-1 receptor agonist class, such as generic dulaglutide (Trulicity).
Does Medicare Part D have an Ozempic prior authorization requirement in 2026?
Yes, virtually all Medicare Part D plans require prior authorization for Ozempic in 2026. Your prescriber must submit documentation confirming a type 2 diabetes diagnosis, typically including recent HbA1c lab values. Many plans also require step therapy documentation showing that metformin or another antidiabetic was tried first. If your plan denies Ozempic, you have the right to request a formulary exception, file an appeal, or ask your prescriber to request a peer-to-peer review with the plan's medical director. Medicare standard appeals must be processed within 7 days; expedited appeals within 72 hours.
What does the 2026 Medicare GLP-1 Bridge program cover, and does it include Ozempic?
The Medicare GLP-1 Bridge is a CMS demonstration program running from July 1, 2026 through December 31, 2027. Eligible Medicare Part D enrollees can access Wegovy (semaglutide injection or tablet), Zepbound (tirzepatide), and Foundayo for weight management at a $50 per month copayment. Ozempic is not included in the GLP-1 Bridge because the program covers only drugs with an FDA-approved weight-loss or obesity indication, and Ozempic's label is for type 2 diabetes only. Medicare continues to cover Ozempic for diabetes under standard Part D formulary rules, separate from the GLP-1 Bridge.
